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The aberrant hyperactivation of Cyclin-dependent kinase 5 (Cdk5), by the production of its truncated activator p25, results in the
formation of hyperphosphorylated tau, neuroinflammation, amyloid deposition, and neuronal death in vitro and in vivo. Mechanisti-
cally, this occurs as a result of a neurotoxic insult that invokes the intracellular elevation of calcium to activate calpain, which cleaves the
Cdk5 activator p35 into p25. It has been shown previously that the p25 transgenic mouse as a model to investigate the mechanistic
implications of p25 production in the brain, which recapitulates deregulated Cdk5-mediated neuropathological changes, such as hyper-
phosphorylated tau and neuronal death. To date, strategies to inhibit Cdk5 activity have not been successful in targeting selectively
aberrant activity without affecting normal Cdk5 activity. Here we show that the selective inhibition of p25/Cdk5 hyperactivation in vivo,
through overexpression of the Cdk5 inhibitory peptide (CIP), rescues against the neurodegenerative pathologies caused by p25/Cdk5
hyperactivationwithout affecting normal neurodevelopment afforded by normal p35/Cdk5 activity. Tau and amyloid pathologies aswell
as neuroinflammation are significantly reduced in the CIP–p25 tetra transgenic mice, whereas brain atrophy and subsequent cognitive
decline are reversed in these mice. The findings reported here represent an important breakthrough in elucidating approaches to
selectively inhibit the p25/Cdk5 hyperactivation as a potential therapeutic target to reduce neurodegeneration.
Introduction
Cyclin-dependent kinase 5 (Cdk5) is a pleiotropic proline-
directed protein kinase primarily involved in regulatingmamma-
lian CNS development (Dhavan and Tsai, 2001). Deregulation of
Cdk5 activity is thought to contribute to the development of
pathological hallmarks found in a number of neurodegenerative
diseases, such as Alzheimer’s disease (AD), Parkinson’s disease,
and amyotrophic lateral sclerosis (Lau et al., 2002; Nguyen and
Julien, 2003; Smith et al., 2003; Cruz and Tsai, 2004). Previous
studies have shown the involvement of p25/Cdk5 in the develop-
ment of AD-like pathology (Patrick et al., 1999; Ahlijanian et al.,
2000). This has led to extensive research on the role of aberrant
p25/Cdk5 activity in the pathogenesis of neurodegenerative dis-
eases (Otth et al., 2002; Town et al., 2002; Noble et al., 2003; Saito
et al., 2007). It has been shown previously that development of
p25/Cdk5-mediated neuropathological hallmarks has been
linked to neuronal death and a subsequent decline in cognitive
function in several p25 transgenic (p25Tg) mouse models (Cruz
et al., 2003;Muyllaert et al., 2008). It is important to note that the
involvement of p25 in AD is debated by several groups
(Takashima et al., 2001; Bian et al., 2002), with some groups
unable to find elevated p25 levels in AD samples (Yoo and Lubec,
2001; Tandon et al., 2003). However, mechanistic production of
p25 from the Cdk5 activator p35 through the activation of cal-
pain by excitotoxicity and deregulation of calcium homeostasis
to produce an aberrant Cdk5 activity have been reported by sev-
eral groups (Patrick et al., 1999; Lee et al., 2000; Nath et al., 2000).
Previously, the identification of a specific fragment of p35, the
Cdk5 inhibitory peptide (CIP), displayed a specific inhibitory
effect on p25/Cdk5 activity in vitro, without affecting “normal”
p35/Cdk5 activity (Zheng et al., 2002, 2005). To extend these
findings in vivo, we developed a Tgmouse that overexpressedCIP
constitutively in the forebrain under the direction of the Camk2a
promoter. These novel CIP transgenic (CIPTg) mice appeared
phenotypically and developmentally normal with normal Cdk5
function. Additionally, CIP, when co-overexpressed with p25 in
CIP–p25 tetra transgenic (TetraTg)mice, was able to reduce p25-
mediated neurodegeneration. Behavioral studies showed im-
proved cognitive performance in TetraTg mice compared with
p25Tg mice. Last, our data from magnetic resonance imaging
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(MRI) studies show that the loss of whitematter and shrinkage in
brain volume in the p25Tg mice were rescued by CIP expression
in TetraTg mice.
This is the first time that p25/Cdk5 hyperactivity has been
targeted in vivowithout affecting p35/Cdk5 activity, therefore not
affecting normal neurodevelopment. This study breaks away
from the use of ATP analogs to inhibit Cdk5 activity that has
been a barrier in the development of Cdk5 inhibitors. The
results reported here represent a significant step forward in the
in vivo inhibition of the p25/Cdk5 mechanisms involved in
neurodegeneration.
Materials andMethods
Animal handling. All animal experiments were performed according to
approved protocols by the Institutional AnimalCare andUseCommittee
of the National University of Singapore.
Generation of CIPTg mice. The CIP transgene with a FLAG-tag se-
quence and 5- 3 homology arms were generated from the cDNA (p35
pCDNA) by PCR using primers with inbuilt EcoRI restriction sites. This
transgene was then cloned together with human ubiquitin promoter
(UbiC), loxP-flanked STOP cassette, and PGK–neo selection cassette
into the ROSA 26 vector (Ozgene). The entire vector was sequenced to
confirm correct assembly. The vector was linearized with AclI and elec-
troporated intoW9.5 embryonic stem (ES) cells. ES cells carrying theCIP
transgene were microinjected into fertilized C57BL/6 mouse eggs and
reimplanted into pseudo-pregnant C57BL/6 females. The resulting chi-
meras were crossed with C57BL/6 mice to produce the germ-line found-
ers (129Sv/J transgenic mice; Ozgene). Founders were screened by PCR
with specific primers (5-GTGCCTGGGTGAGTTTCTCT-3, 5-CAT-
CGTCGTCCTTGTAATCG-3) directed to the FLAG sequence. The
germ-line founders were then crossed with Camk2A–CRE transgenic
mice [B6.Cg–Tg (Camk2a–Cre) T29–1StI/J] (The Jackson Laboratory)
to get the bitransgenic mice (CIPTg mice), which express CIP in the
forebrain using the CRE/LoxP recombination system. Furthermore,
CIPTgmice were crossed with p25Tgmice (offspring from themating of
C57BL/6–Tg (tetO–CDK5R1/GFP) 337Lht/J (The Jackson Laboratory)
with Camk2a transgenic mice B6; CBA–Tg (Camk2a–tTA) 1Mmay/J
(The Jackson Laboratory) (Cruz et al., 2003) to get the TetraTgmice that
overexpress both the CIP and p25 genes. Inducible p25 gene expression
was controlled by the tetracycline derivative doxycycline. TetraTg mice
and p25Tgmice in this studywere conceived and raised in the presence of
doxycycline (200g/ml; Sigma) in drinkingwater for 6weeks postnatally
to avert any potential developmental consequences from the expression
of p25. Littermates of the same sex were used for comparison whenever
possible.
Antibodies.Antibodies used for bothWestern blot analyses and immu-
nohistochemistry were mouse monoclonal anti-FLAG (1:200; Sigma),
rabbit polyclonal anti-Cdk5 (C8, 1:500; Santa Cruz Biotechnology),
mousemonoclonal anti-cytosolic phospholipase 2 (cPLA2) (1:200; Santa
Cruz Biotechnology), rabbit monoclonal anti-phospho-glycogen syn-
thase kinase-3 (GSK-3) (Ser9; 1:1000; Cell Signaling Technology),
mouse anti--tubulin (1:10,000; Sigma), mouse monoclonal anti-GFP
(1:500; Roche), mouse monoclonal anti-GFAP (1:1000; Sigma), mouse
monoclonal anti-Cd11b (1:200; Millipore), mouse monoclonal anti-
paired helical filaments (PHF)–tau antibodies (clones AT8 and AT180,
1:100; Pierce), mouse monoclonal anti--amyloid 1–42 (1:100; Milli-
pore), mousemonoclonal anti--amyloid 1–16 (6E10), and anti-cleaved
caspase-3 antibody (1:200; Cell Signaling Technology). Secondary
fluorescence-conjugated antibodies Alexa Fluor 488 and Alexa Fluor 594
(Invitrogen) were used at 1:200 dilutions for immunohistochemistry.
Horseradish peroxidase-conjugated mouse or rabbit secondary anti-
bodies (GEHealthcare) were used at 1:1000 dilutions forWestern blot
analyses.
Histochemical studies. CIPTg, p25Tg, and TetraTg mice were anesthe-
tized with the mixture of ketamine (75 mg/kg) and medepomidin (1
mg/kg) and transcardially perfused with freshlymade 4%PFA/PBS. Cry-
ostat brain sections of 16 m thickness were collected, and immunoflu-
orescence staining was performed according to our previously published
protocol (Sundaram et al., 2012). Thioflavin-S stainingwas performed as
described previously with slight modification (Sun et al., 2002). Sections
were stained with 0.05% thioflavin-S in 50% ethanol in the dark for 10
min. This step was followed by differentiation in two changes of 50%
ethanol for 10 s each and two washes in large volumes of distilled water.
Confocal images were taken at 40 magnification. Nissl and Biel-
schowsky silver staining were performed according to the previously
published protocols (Litchfield and Nagy, 2001).
TUNEL staining. TUNEL staining was performed according to the
instructions of the manufacturer using the In Situ Cell Death Detection
Kit, TMR red (Roche).
Western blot analyses. Brain lysates from CIPTg, p25Tg, and TetraTg
mice were prepared as described previously (Kesavapany et al., 2004).
Polyacrylamide gel running, nitrocellulose membrane transfer, and de-
tection were performed as reported previously (Sundaram et al., 2012).
[-32P]ATP kinase assay. Kinase assays to investigate the changes in
Cdk5 activity were performed using brain lysates from CIPTg, p25Tg,
and TetraTg mice as described in our previous publication (Poore et al.,
2010).
Immunoprecipitation and coimmunoprecipitation assay. Immunopre-
cipitation was performed according to the protocol published previously
((Poore et al., 2010). Briefly, lysates from brain samples of wild-type
(WT) and CIPTg mice were precleared with protein G-Sepharose beads
(Sigma) for 1 h at 4°C. Precleared protein (500g)was incubatedwith 10
g of mouse monoclonal anti-Cdk5 (J3; Santa Cruz Biotechnology) for
3–4 h at 4°C, and proteinG-Sepharose beadswere added to the lysates for
overnight incubation at 4°C. Coimmunoprecipitated proteins were then
immunodetected using rabbit polyclonal anti-p35 (C19, 1:500; Santa
Cruz Biotechnology) and rabbit polyclonal anti-p39 (1:1000; Cell Signal-
ing Technology) antibodies.
cPLA2 activity assay. cPLA2 activity assay was performed according to
the instructions of the manufacturer using cPLA2 Activity Assay Kit
(Cayman Chemical). The results were normalized against protein con-
centration determination by BCA assays (Pierce Biotechnology).
Lipids analysis using HPLC mass spectrometry. Lipid extraction and
mass spectrometry was performed as published previously using the
brain samples from p25Tg, CIPTg, and TetraTg mice (Sundaram et al.,
2012).
MRI.CIPTg, p25Tg, and TetraTgmice underwentMRI to observe the
brain morphological changes between different animal groups in vivo.
Manganese enhanced MRI was used to enhance contrast of different
brain regions for better visualization of cytoarchitecture in anatomical
imaging (Aoki et al., 2004). Animals were administered slowly with 0.1 M
MnCl2 at a dosage of 80 mg/kg body weight via intraperitoneal injection
with an infusion pump at a rate of 0.25 ml/h. Imaging experiments were
performed between 1 and 1.5 d after the administration of MnCl2 (Aoki
et al., 2004; Chuang and Koretsky, 2006). Magnetic resonance images
were acquired on a 9.4 tesla scanner with 31 cm horizontal bore magnet
interfaced to Varian console (Agilent Technologies). A 72-mm-inner-
diameter volume coil (Rapid Biomedical) was used for the transmission
of radio frequency wave, and a custom-designed 15 mm single-loop
surface coil was placed on the animal’s head as the receive coil. Images
were acquired using T1-weighted 3D magnetization-prepared rapid ac-
quisition with gradient echo sequence with the following: repetition
time, 8 ms; echo time, 2.60 ms; flip angle, 10 °; inversion time, 1.0 s;
matrix size, 256 192 128; and field of view, 25.6 19.2 12.8mm3.
Nine averages were acquired in 90 min to increase signal-to-noise ratio.
The images were then zero filled and reconstructed to a matrix size of
256  256  128, resulting in a final resolution of 0.1  0.075  0.1
mm3.
Radial maze. The radial arm maze paradigm was performed as re-
ported previously (Zou et al., 1998; Schmitt et al., 2003), with slight
modificationsmentioned below. Themaze consisted of eight arms, num-
bered from 1 to 8, extending radially from the central area (5 cm lane
width  35 cm arm length  9 cm wall height; Stoelting ANY-maze).
Visual cues (black and white images) were placed in the arms 2, 4, 6, and
8 (at the end of each arm). In the training phase,mice were given 7min to
explore all the arms and eat the novel food (fruit loops) that were placed
in only one arm in the order of 2, 4, 6, or 8 each session. The apparatus
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was cleaned with 70% ethanol and dried between trials. Novel food was
also placed outside of all the arms to minimize the possibility of smell as
a cue. During the test phase, mice were placed individually in the center
of the maze and subjected to reference and working memory tasks for
10 d, with the same four arms (numbers 2, 4, 6, and 8) baited in each of
the trial. The test trial continued until all four baits had been consumed
or until 5 min had elapsed. Measures were made of the number of refer-
ence memory errors (entering an arm that was not baited), working
memory errors (entering an arm containing food but previously en-
tered), and also the total time taken to finish the task. Mice were given
one test session per day, 5 d/week during the period of behavioral testing.
The test and training sessions were performed in the same time of day in
a moderately lit room with standard conditions of temperature and free
from any stray noise.
Statistics. All values are expressed as the mean of at least three deter-
minations SEM. Data were analyzed by Student’s t test, and p value
0.05 was considered to indicate statistical significance. For radial maze
analyses, workingmemory errorswere plotted by themice over the entire
test sessions averaged and subjected to one-way ANOVA, followed by
post hoc Tukey’s test. The reference memory errors counted during the
test sessions were plotted as bins of 1 d each and subjected to repeated-
measures ANOVA, followed by post hoc Tukey’s test.
Results
Generation and characterization of mice overexpressing
CIP transgene
We generated CIPTg mice that overexpressed CIP in the fore-
brain under the control of Camk2a promoter using the Cre/LoxP
recombination system. The CIP transgene was tagged with the
FLAG epitope (Fig. 1A). To examine the CIP transgene expres-
sion pattern in CIPTg mice brain, immunohistochemistry (Fig.
1B,C) andWestern blot analyses (Fig. 1D, second panel, E) were
performed on the brain samples of CIPTg and WT control mice
using the anti-FLAG antibody. Results confirmed the robust
forebrain-specific expression of CIP, which was increased with
increasing age in CIPTgmice compared with theWTmice. It has
been reported previously that CIP expression does not affect en-
dogenous Cdk5 activity of neurons in vitro (Kesavapany et al.,
2007). Hence, we wanted to test the effect of CIP overexpression
on endogenous Cdk5 activity in vivo in CIPTg mice using West-
ern blot analyses (Fig. 1D, top panel, E) and kinase assays (Fig.
1F). We did not observe any significant changes in endogenous
Cdk5 activity and expression levels inCIPTgmice comparedwith
WTmice. Coimmunoprecipitation assays were performed to in-
vestigate the effect of CIP on the interaction of Cdk5 with its
activators p35 and p39 using CIPTg and WT mice brain lysates
(Fig. 1G,H). Results showed that the normal Cdk5/p35 or Cdk5/
p39 interactions were not significantly affected by CIP expression
in CIPTg mice. To examine further whether CIP overexpression
causes any structural changes in CIPTgmice brain, we performed
MRI of the mice. The results validate that overall brain morphol-
ogy and organization in CIPmice appear normal (Fig. 1I). Addi-
tionally, Nissl staining showed no changes in cortical patterning
Figure1. Characterizationof CIPTgmice.A, The CIPTg construct contains a 3-FLAG-taggedCIP transgene incorporated in to theROSA26 locuswhose5 regulatory elementswere separated from
the coding regionwith a floxed stop sequence. A frt-flanked neomycin resistance (Neo) cassette was inserted next to the transgene before the 3 homology arm. Representative confocal images of
frontal cortex (layer 2/3) (B) and hippocampus (CA3 region) (C) from 6-week-old and 18-week-oldWT and CIPTgmice. The sectionswere immunostainedwith anti-FLAG antibody (red), and nuclei
were counterstained with DAPI (blue). D, Immunoblot analyses of brain lysates from WT and CIPTg mice using anti-Cdk5 (C8) and anti-FLAG antibodies. Equal amounts of protein loading were
confirmed by reprobing the membrane with anti-tubulin antibody. E, Quantification of immunoblot analyses in D by densitometric scanning (n 3) (***p 0.001 and NSp 0.05). F, Kinase
assays using active kinase (Cdk5) fromWT and CIPTg mice brains to phosphorylate a high-molecular-weight neurofilament (NF-H) peptide ( NSp 0.05). G, WT and CIPTg mice brain lysates were
immunoprecipitated (IP) using anti-Cdk5 (J3) antibody. Samples were separated by SDS-PAGE and immunoprobed with anti-p35, anti-p39, and anti-Cdk5 (C8) antibodies. H, Quantification of
immunoblot analyses inGbydensitometric scanning ( NSp0.05).MRI scanning images of coronal slices (I ) andNissl staining images of frontal cortex (J ) fromWTandCIPTgmicebrains. Scale bars,
20m. Data are representative of n 4 mice. Error bars indicateSEM.
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between themice (Fig. 1J). Together, our results indicate that the
endogenous Cdk5 level, activity, and the normal brain develop-
ment were not affected by CIP overexpression in CIPTg mice.
CIP overexpression specifically inhibits p25/Cdk5
hyperactivation in TetraTg mice
To study the ability of CIP to specifically inhibit the p25/Cdk5
hyperactivation-mediated neurodegeneration in vivo, we gener-
ated a TetraTg mouse that overexpresses p25 and CIP under the
direction of the Camk2a promoter. TetraTgmice were generated
by crossing the CIPTg mice with the p25/Camk2a bitransgenic
mice [p25Tg mice generated by crossing C57BL/6–Tg (tetO–
CDK5R1/GFP) 337Lht/J (The Jackson Laboratory)mice with B6;
CBA–Tg (Camk2a–tTA) 1Mmay/J (The Jackson Laboratory)
mice]. Immunohistochemistry and Western blot analyses were
performed using anti-GFP and anti-FLAG antibodies to confirm
the expression of both p25 and CIP transgene in the forebrain of
the TetraTg mice (Fig. 2A,B). To examine the effect of CIP over-
expression on the p25-mediated Cdk5 hyperactivation, we per-
formed Western blot analyses and in vitro kinase assays on the
samples from12week induced p25Tg, TetraTg, and age-matched
CIPTg mice brains. No significant changes in the Cdk5 expres-
sion levels were observed among all the samples (Fig. 2B). How-
ever, there was a significant increase in Cdk5 activity in p25Tg
mice compared with the CIPTg mice. In contrast, Cdk5 activity
was reduced inTetraTgmice comparedwith the p25Tgmice (Fig.
2C). Collectively, these results suggest that p25-induced Cdk5
hyperactivation was effectively inhibited by CIP overexpression
in TetraTg mice. GSK-3 is another principal kinase thought to
phosphorylate tau and involved in neurodegeneration (Ferrer et
al., 2002). To study whether CIP expression has any effect on the
GSK-3 activity, Western blot analyses were performed on the
samples from p25Tg, TetraTg, and CIPTg mice using anti-
phospho-GSK-3 (Ser9) antibody (Fig. 2D,E). It has already
been proved that GSK-3 activity is negatively regulated by its
phosphorylation at serine 9 (Jope and Johnson, 2004). Our re-
sults determine that GSK-3 activity was significantly decreased
in p25Tg mice in which, as in TetraTg mice, GSK-3 activity
increased to levels similar to control CIPTg mice.
CIP reduces p25/Cdk5-mediated neuroinflammation in
TetraTg mice
We have shown previously that robust neuroinflammation oc-
curred in the p25Tgmice (Sundaramet al., 2012). To examine the
effect of CIP expression on p25-mediated astrogliosis andmicro-
gliosis, we preformed immunohistochemistry and Western blot
analyses using GFAP (marker for astrocytes) and Cd11b (marker
for microglia) antibodies on the samples from 12 week induced
p25Tg, TetraTg, and age-matched CIPTg mice brains. CIP ex-
pression on its own did not induce any astrogliosis and micro-
gliosis. Whereas p25 expression elevated GFAP and Cd11b
expression levels in p25Tg mice, in contrast, astrogliosis and mi-
crogliosis were significantly reduced in TetraTg mice compared
with p25Tg mice (Fig. 3A–C). We have shown previously that
p25/Cdk5 hyperactivation caused cPLA2 upregulation to pro-
duce the soluble lipid mediator lysophosphatidylcholine (LPC),
which mediated neuroinflammation in p25Tg mice (Sundaram
et al., 2012). To investigate the effect of CIP overexpression on
Figure 2. Characterization of TetraTg mice. A, Immunofluorescence images of frontal cortex (layer 2/3) from 12 week induced p25Tg mice, TetraTg, and their respective age-matched CIPTg
controlmice. The sectionswere immunostainedwith anti-GFP antibody (green) and anti-FLAG antibody (red). Nuclei were counterstainedwith DAPI (blue).B, Immunoblot analyses of brain lysates
from 12 week induced p25Tg, TetraTg, and the CIPTg mice using anti-GFP, anti-FLAG, and anti-Cdk5 (C8) antibodies. C, Representative in vitro kinase assays using active kinase (Cdk5) immuno-
precipitated fromthep25Tg, TetraTg, andCIPTgmice (**p0.001, ***p0.0001, NSp0.05).D,Westernblot analyses of brain lysates from12week inducedp25Tg, TetraTg, and theCIPTgmice
using anti-phospho-GSK-3 (Ser9) antibody.E, Quantification of immunoblots inDbydensitometric scanning (*p0.05, **p0.001, NSp0.05). Scale bars, 20m.Error bars indicateSEM.
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this mechanism, Western blot analyses, cPLA2 activity assays,
and mass spectrometry analyses were performed using the brain
samples fromp25Tg, TetraTg, andCIPTgmice (Fig. 3D–G).Data
indicated that p25-mediated cPLA2 upregulation and LPC pro-
duction were significantly reduced in TetraTg compared with
p25Tg mice but not to basal/control levels. Together, our results
confirmed that LPC upregulation could be affected in part by
CIP expression, but there may be distinct pathways that are
responsible for cPLA2 upregulation by p25 and p25/Cdk5 ac-
tivity inhibition.
CIP reduces p25/Cdk5-mediated tau phosphorylation and
amyloid accumulations in TetraTg mice
Previous studies already proved that CIP can inhibit the p25/
Cdk5 hyperactivation-mediated tau hyperphosphorylation and
-amyloid accumulation in vitro (Zheng et al., 2005). To confirm
this finding in vivo, we performed immunohistochemistry and
Western blot analyses using a number of phospho-tau antibod-
ies.We found that there was a reduction in AT8 and AT180 levels
in TetraTg mice compared with p25Tg mice (Fig. 4A–C). This
was also confirmed with AT100 and AT270 antibodies (data not
shown). Our results show that CIP significantly inhibited p25-
mediated tau hyperphosphorylation in TetraTg mice. To inves-
tigate whether the CIP overexpression affects the p25-induced
-amyloid accumulation in TetraTg mice, immunofluorescence
and thioflavin-S staining experiments were performed. Results
showed an almost total reduction in -amyloid and thioflavin-S
staining in TetraTg mice compared with p25Tg mice (Fig. 4D,E,
top panel). Additionally, Bielschowsky silver staining results fur-
ther confirmed our findings (Fig. 4E, bottom). Collectively our
results showed that CIP effectively reduces the development of
p25/Cdk5-mediated tau and amyloid neuropathological hall-
marks in vivo.
CIP reduces neuronal apoptosis and forebrain atrophy
mediated by p25/Cdk5
Grossmorphological changes and severe atrophy of the forebrain
are prominent features of p25Tg mice (Cruz et al., 2003, 2006;
Sundaram et al., 2012). Therefore, we set out to determine the
effect of CIP on the p25-mediated neuronal apoptosis in TetraTg
mice. We used cleaved caspase-3 expression as a marker of
apoptosis (Nicholson et al., 1995). Results from immunohisto-
chemistry and Western blot analyses revealed that caspase-3 ex-
pression was increased fivefold in p25Tg compared with the
CIPTg mice. This p25-induced caspase-3 overexpression was al-
most completely abolished in TetraTg mice (Fig. 5A, bottom,
C,D). We performed TUNEL assays as an additional measure of
apoptosis, and results confirmed that there was a 75% increase in
the number of TUNEL-positive cells in the brain sections of
p25Tg mice compared with the CIPTg mice. However,20% of
TUNEL-positive cells was observed in TetraTgmice (Fig. 5A, top,
B). Figure 5E shows the considerable reduction in forebrain size
in p25Tg mice compared with CIPTg and TetraTg mice. There
was no significant difference in size of the brain of the TetraTg
Figure3. Reducedneuroinflammation in TetraTgmice.A, Representative confocal images of frontal cortex from12week inducedp25Tg, TetraTg, andCIPTgmice. Thebrain sectionswere labeled
with anti-GFAP antibody (green), anti-Cd11b antibody (red), and nuclei were stained with DAPI (blue). B, Western blot analyses of brain lysates from p25Tg, TetraTg, and the CIPTg mice using
anti-GFAP and anti-Cd11b antibodies. C, Quantification of immunoblots inB by densitometric scanning (***p 0.001).D, Immunoblot analyseswere performed on lysates from the samples same
as inBusing anti-cPLA2 antibody. E, Quantification of immunoblot analyses inD (*p 0.05, NSp 0.05). F, cPLA2 activity assayswere performedwith lysates fromp25Tg, TetraTg, and CIPTgmice
(*p 0.05, NSp 0.05, ***p 0.001). G, Results from the mass spectrometric analyses for the p25Tg, TetraTg, and CIPTg mice brain samples. Results were normalized against the internal
standards of LPC (*p 0.05, **p 0.01). Scale bars, 20m. Data are representative of n 4 mice. Error bars indicateSEM.
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compared with the CIPTg mice. We also determined the gross
brain weight of the p25Tg, TetraTg, and CIPTg mice, and the
quantification graph in Figure 5F shows that there was a signifi-
cant reduction in brain weight of the p25Tg mice compared with
CIPTg and TetraTg mice, with no significant difference in the
brain weight of the TetraTgmice compared with CIPTg. In sum-
mary, our results show that CIP expression rescued against p25-
induced neuronal apoptosis. To further determine the cortical
patterning in TetraTg mice, we performed Nissl histology stain-
ing. Severe neuronal patterning deficits were observed in the cor-
tical layers as well as in the hippocampus of the p25Tg mice
compared with the CIPTg mice. Cortical and hippocampal pat-
terning were unchanged in TetraTg mice compared with CIPTg
mice (Fig. 5G). In vivo brain imaging using MRI on the p25Tg,
TetraTg, and CIPTg mice was performed to show cortical
shrinkage and cerebral ventricular enlargement in p25Tg mice
compared with the CIPTg mice. Significant reductions in p25-
mediated cortical shrinkage were observed in the TetraTg mice
(Fig. 5H, I). Together, our results provide compelling evidence
that CIP expression effectively reduces the p25-mediated fore-
brain atrophy and neurodegeneration.
CIP expression abolished p25-mediated neurocognitive
deficits in TetraTg mice
We wanted to address the question whether this CIP rescue
against neuropathology and apoptosis translates to a benefit in
cognitive function. Radial arm maze paradigm showed signifi-
cant increases in both number of reference and workingmemory
errors in p25Tg mice compared with CIPTg mice. In contrast,
TetraTg mice made very few reference and working memory er-
rors compared with p25Tg mice (Fig. 6A,B). Together, our re-
sults confirm that TetraTgmice showed superior performance in
this spatial memory task compared with the p25Tg mice, clearly
demonstrating that CIP hyperexpression reverses the cognitive
deficits of p25/Cdk5 hyperactivation in TetraTg mice.
Discussion
In this study, we show that in vivo expression of CIP, a 125 aa
peptide derived from p35, effectively and specifically inhibits the
hyperactivation of p25/Cdk5. These data are an extension to the
in vitro findings detailing CIP protection in primary neurons
(Zheng et al., 2005). In addition, this is the first time p25/Cdk5
aberrant hyperactivation has been selectively targeted in vivo.
Previous attempts to target Cdk5 activity have not been success-
ful in targeting normal versus aberrant Cdk5 activity attributable
to inhibitors primarily being ATP analogs. This resulted in inhi-
bition of both normal p35/Cdk5 as well as aberrant p25/Cdk5
activities causing neurodevelopmental issues because it is well
established that targeting normal p35/Cdk5 activity will result in
CNS organizational deficits, synaptic dysfunction, and defects in
the migration of neurons (Tsai et al., 1994; Leost et al., 2000;
Leclerc et al., 2001). It is therefore critical to selectively target the
Figure 4. Inhibition of p25-mediated phospho-tau and -amyloid accumulation in TetraTg mice. A, Immunofluorescence images of frontal cortex from p25Tg, TetraTg, and their respective
age-matched CIPTg mice using AT8 (PHF–tau) and AT180 (PHF–tau) (red) antibodies. DAPI-stained nuclei appear blue. B, Hyperphosphorylated tau protein levels were analyzed by Western blot
analyses using AT8 and AT180 antibodies. C, Quantification of immunoblots in B by densitometric scanning (***p  0.001). D, Brain sections from p25Tg, TetraTg, and CIPTg mice were
immunostainedwith A1–42 and 6E10 (A1–16) (green). Nuclei were stainedwith DAPI (blue). E, Thioflavin-S staining (top) and Bielschowsky silver staining (bottom) images of the brain sections
from p25Tg, TetraTg, and CIPTg mice. Scale bars, 20m. Data are representative of n 4 mice. Error bars indicateSEM.
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aberrantly hyperactive Cdk5 form that causes the pathological
hallmarks of tau hyperphosphorylation and amyloid accumula-
tions formed by a neurotoxic or excitotoxic insult in the CNS.
There has been some dispute about the role of p25 in the
development of AD-like pathology that has been attributed to
differences in tissue collection and preparation protocols (Ker-
okoski et al., 2001; Takashima et al., 2001; Bian et al., 2002). In
our hands and others, we have consistently observed that the
overexpression of p25 causes a robust increase in Cdk5 activity
leading to phosphorylated tau and neuronal death both in vitro
and in vivo (Cruz et al., 2003; Muyllaert et al., 2008; Sundaram et
al., 2012). Mechanistically, the formation of p25 is consistent
with the well-documented hypothesis of excitotoxicity in neu-
rons undergoing degeneration. Calcium influx, as a result of
overactivation of calcium-mediated channels such as NMDARs,
activate calpain, which then cleaves a normally membrane-
boundp35 to generate p25 that has a longer half-life with a potent
Cdk5 hyperactivation profile (Patrick et al., 1999; Lee et al.,
2000).
Previous studies identified a central fragment of p35 (residues
154–279), called CIP, that can effectively inhibit Cdk5 activity in
vitro (Amin et al., 2002; Zheng et al., 2002). Additional studies
identified CIP as a potent, selective inhibitory peptide toward
p25/Cdk5 without affecting p35/Cdk5 activity (Zheng et al.,
2005). As an extension of these studies and a validation of those
findings in vivo, we generated the CIPTg mouse model that was
crossed with region-specific Camk2a–Cre mouse to allow CIP
expression in the forebrain. These mice constitutively expressed
Figure5. CIP expression rescues p25-inducedbrain atrophy in TetraTgmice.A, Representative confocal images of frontal cortex from12week inducedp25Tg, TetraTg, andCIPTgmice. Top shows
the TUNEL staining images (red), and the bottom shows the immunofluorescence stainingwith cleaved caspase-3 antibody (green). Nuclei were counterstainedwith DAPI (blue).B, Percentage cell
death in bottom of Awas calculated by counting the TUNEL-positive cells normalized with DAPI from 10 independent fields (***p 0.001). C, Western blot analyses of brain lysates from 12week
induced p25Tg, TetraTg, and CIPTgmice using anti-cleaved caspase-3 antibody. D, Quantification of immunoblots in C by densitometric scanning (***p 0.001). E, Whole-brain photos showing
the levels of forebrain atrophy in CIPTg, p25Tg, and TetraTgmice. F, Quantification of brain weight from p25Tg, TetraTg, and CIPTgmice (***p 0.0001 and NSp 0.05).G, Nissl staining images
of frontal cortex as well as CA3 region of the hippocampus from the p25Tg, TetraTg, and CIPTg control mice.H, I, Representativemagnetic resonance images of sagittal, transverse, and axial planes
of the CIPTg, p25Tg, and TetraTg mice. White rectangular boxes, arrowheads, and arrows indicate the level of cortical atrophy between the three groups of mice. Scale bars, 20 m. Data are
representative of n 4 mice. Error bars indicateSEM.
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CIP under the Camk2a promoter at relatively stable levels, prob-
ably attributed to the ROSA26 locus in which the transgene was
inserted. Based on previous in vitro evidence, we believed that
normal Cdk5 activity would not be affected in the CIPTg mice
(Zheng et al., 2005), and our results confirmed that CIPTg mice
were phenotypically identical to WT C57BL/6 mice in terms of
nervous system development, body weight, and behavior. In ad-
dition, normal Cdk5/p35 or Cdk5/p39 interactions were not af-
fected by CIP expression in CIPTg mice. Previously, we
extensively characterized the p25Tgmice that were first described
to be a robust model that exhibit AD-like neuropathology (Cruz
et al., 2003, 2006). We found extensive phosphorylation of tau
beginning at 4 weeks, whereas amyloid accumulations were ap-
parent beginning at 8 weeks. We also found neuroinflammation
as an early event in the p25Tgmice, occurring only after 1 week of
p25 expression induction (Sundaram et al., 2012).
To determine whether CIP could selectively reduce p25/
Cdk5-mediated neuroinflammation and neurodegeneration, we
crossed our CIPTg mice with the p25Tg mice to generate the
TetraTgmice that overexpress both CIP and p25 in the forebrain.
Neuroinflammation was extensively decreased in both microgli-
otic and astrogliotic paradigms in TetraTg mice. In addition,
Cdk5/p25-mediated cPLA2 upregulation and LPC production
were markedly reduced in TetraTg mice compared with p25Tg
mice. However, LPC levels in TetraTg mice were not reduced to
the levels of control CIP mice. This explains why microgliosis/
astrogliosis were not completely abolished in TetraTg mice. The
data generated here suggest that cPLA2-mediated neuroinflam-
mation and neurodegeneration, at least in part, function through
a distinct mechanism, and CIP-mediated inhibition of p25/Cdk5
activity may not be sufficient to completely block p25
overexpression-mediated cPLA2 upregulation. Moreover, the
hallmark formations of hyperphosphorylated tau and amyloid
accumulations were drastically reduced in these mice compared
with the p25Tg mice. Previous reports proved that Cdk5 nega-
tively regulates GSK-3 through the activation of protein phos-
phatase 1 (Morfini et al., 2004). Besides, studies also suggest that
Cdk5/p25 hyperactivation inhibits GSK-3 activity by enhancing
the inhibitory phosphorylation at serine 9 of GSK-3 only in
young p25Tg (Plattner et al., 2006; Wen et al., 2008). However,
our results indicate that GSK-3 activity
in 12 week induced p25Tgmouse was sig-
nificantly decreased compared with the
control mice, therefore suggesting that
GSK-3 is actually not responsible for the
tau phosphorylation in the p25Tg mice.
Additionally, in the TetraTg mice,
GSK-3 activity is increased, therefore
not correlating with decreased tau
phosphorylation.
To ensure that the reductions of p25/
Cdk5 activity, phosphorylated tau, and
amyloid formation manifested in neuro-
protection and cognitive benefit, we used
MRI in these mice as well as behavioral
cognitive assessments. Together, the over-
expression of CIP in the p25Tgmodel res-
cued the cortical atrophy caused by p25
overexpression and also corrected the
cognitive deficits monitored by radial
maze study, showing that CIPwas respon-
sible for the neuroprotection observed.
Obvious extensions to this study is to
cross the CIPTg with other models in which p25/Cdk5 activity
has been found, such as the amyloid precursor protein transgenic
and P301L models (Lewis et al., 2000; Yu et al., 2012), which
would be an extension of the proof of concept for CIP. The p25Tg
model provides an opportunity to study a mechanism-mediated
model of neurodegeneration in which aberrant Cdk5 hyperacti-
vation is involved. Increased activation of Cdk5 as well as early
onset of neuroinflammation has also been observed in other
mousemodels that have been used to study disease (Oakley et al.,
2006; Yu et al., 2012).
Additionally, the CIP model may be of potential use in non-
CNS indications inwhichCdk5 activity has been implicated, such
as pancreatic  cells and involvement in diabetes (Daval et al.,
2011). Progression of CIP studies has identified a smaller 24 aa
peptide derived by serial truncation of CIP. This 25 aa peptide
(termed as P5) has been shown to inhibit p25/Cdk5 activity in
transfected HEK cells as well as transduced primary neurons, but
in vivo studies are ongoing now (Zheng et al., 2010). The possi-
bility of these peptides, CIP and P5, generating information
about a selective small molecule inhibitor is low, but the use of
these molecules in a biologics manner in vivo is a definite possi-
bility. Additionally, in the quest to find a smallmolecule inhibitor
in the mold of CIP and P5, encoded ligand technology can be
used to identify compounds that mimic a P5 and CIP binding to
Cdk5.
Using the collective data from the specific inhibition fromCIP
in the presence of p25 in TetraTg mice will afford better under-
standing of Cdk5 hyperactivation in neurodegeneration. The
knowledge gained from our study will develop possible strategies
to produce a specific p25/Cdk5 inhibitor that will reduce pathol-
ogy in neurodegenerative diseases in which aberrant Cdk5 activ-
ity caused by the formation of p25 has been implicated in the
disease process.
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